{"disease":{"id":"mpr","name":"mpr"},"drugs":{"marketed":[{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"dopamine-hydrochloride","indication_name":"Improving hemodynamic status in distributive shock","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOPAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":11,"revenue":null,"mechanism":null},{"drug_id":"dopamine-hydrochloride","indication_name":"Improving hemodynamic status in shock due to reduced cardiac output","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOPAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":11,"revenue":null,"mechanism":null},{"drug_id":"aspart","indication_name":"Improving glycemic control","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aspart","company_name":"Emory University","drug_phase":"marketed","molecular_target":"Aminoacylase-1, Argininosuccinate synthase, Aspartate aminotransferase, cytoplasmic","drug_class":"Insulin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"dextromethorphan-hydrobromide","indication_name":"Improved Nasal Breathing","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DEXTROMETHORPHAN HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Expectorant [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"celery-seed","indication_name":"Improving sexual desire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Celery Seed","company_name":"University of Guadalajara","drug_phase":"marketed","molecular_target":"","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"acyclovir-sodium","indication_name":"Herpes Simplex in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ACYCLOVIR SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"acyclovir-sodium","indication_name":"Varicella-Zoster in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ACYCLOVIR SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"dimethyl-sulfoxide","indication_name":"Improvement of symptoms in patients with interstitial cystitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimso-50","generic_name":"DIMETHYL SULFOXIDE","company_name":"Mylan Institutional","drug_phase":"marketed","molecular_target":"","drug_class":"dimethyl sulfoxide","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with other conditions that compromise the immune system.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"ertugliflozin-15-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 15 mg","generic_name":"ertugliflozin-15-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis B (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Hepatitis A (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Zoster (shingles) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (seasonal) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (H1N1) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Varicella (chickenpox) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Pneumococcal disease (PCV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Zoster (shingles) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (seasonal) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Influenza (H1N1) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Human papillomavirus (HPV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Varicella (chickenpox) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenACWY) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Meningococcal disease (MenB) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Pneumococcal disease (PCV) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Cultured Autologous Osteoblasts for the Treatment of Vertebral Compression Fractures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isoproterenol","indication_name":"Improving hemodynamic status in distributive shock","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISOPROTERENOL","company_name":"","drug_phase":"marketed","molecular_target":"beta-adrenergic receptors","drug_class":"Beta-adrenergic agonist","quality_score":80,"revenue":null,"mechanism":"Isoproterenol activates beta-adrenergic receptors without affecting alpha-adrenergic receptors."},{"drug_id":"cidofovir","indication_name":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vistide","generic_name":"CIDOFOVIR","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"cidofovir","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"isoproterenol","indication_name":"Improving hemodynamic status in shock","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISOPROTERENOL","company_name":"","drug_phase":"marketed","molecular_target":"beta-adrenergic receptors","drug_class":"Beta-adrenergic agonist","quality_score":80,"revenue":null,"mechanism":"Isoproterenol activates beta-adrenergic receptors without affecting alpha-adrenergic receptors."},{"drug_id":"recombinant-antithrombin-rhat","indication_name":"Improving Resorption of Radiopaque Agents in Subcutaneous Urography","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Recombinant antithrombin (rhAT)","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"Hyaluronic acid and connective tissue polysaccharides","drug_class":"Dispersion agent; enzyme","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with immunocompromised conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ertugliflozin-5-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 5 mg","generic_name":"ertugliflozin-5-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with immunocompromising conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"CMV Retinitis in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"foscarnet","indication_name":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"vistide","indication_name":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vistide","company_name":"Gustave Roussy, Cancer Campus, Grand Paris","drug_phase":"marketed","molecular_target":"DNA polymerase catalytic subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"repaglinide","indication_name":"Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prandin","generic_name":"repaglinide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family C member 8","drug_class":"Glinide [EPC]","quality_score":10,"revenue":null,"mechanism":"Repaglinide lowers blood glucose levels by stimulating insulin release from the pancreas through ATP-dependent potassium channel blockade."}],"pipeline":[{"drug_id":"prevnar-20","indication_name":"Immunocompromised adults (CLL, HIV, autoimmune)","indication_type":"pipeline","phase":"phase_3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar 20","generic_name":"pneumococcal 20-valent conjugate vaccine (PCV20)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae capsular polysaccharides (20 serotypes)","drug_class":"Pneumococcal conjugate vaccine","quality_score":80,"revenue":"6400","mechanism":"20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes"},{"drug_id":"niacin","indication_name":"Healthspan improvement","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":49,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT00904579","title":"Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease","phase":"","overall_status":"COMPLETED","enrollment_count":19929901,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05020145","title":"COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1277747,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03824990","title":"Multi-center Clinical Study on Neonatal Hyperbilirubinemia","phase":"NA","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"Nanjing Medical University","has_results":false},{"nct_id":"NCT06163222","title":"Behavioural Interventions to Improve Equity in Outpatient Access","phase":"NA","overall_status":"COMPLETED","enrollment_count":13389,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT06331923","title":"Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes","phase":"NA","overall_status":"RECRUITING","enrollment_count":10168,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT06085690","title":"Multicenter Clinical Translational Study of \"ICU-NO CRBSI\" Based on Improvement Science","phase":"NA","overall_status":"RECRUITING","enrollment_count":8050,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07431190","title":"British Columbia Prescriber Feedback Program - Antimicrobial Resistance","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":7626,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT05150249","title":"Prospective Observational Study Based on a Cohort of Geriatric Patients With Hip Fracture Treated in the Centers Belonging to the GIOG Group","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT04195880","title":"Reducing Veterans Hospitalizations From Community Living Centers","phase":"NA","overall_status":"COMPLETED","enrollment_count":6543,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT04211181","title":"CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":5800,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT05817253","title":"Evaluation of Therapeutic Initiative's Cystitis Portrait and Therapeutics Letter","phase":"NA","overall_status":"COMPLETED","enrollment_count":5073,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT04461470","title":"6-Month Outcomes of PEMF to Nucleotide Sources Revealing Cell Sensory Experience in Pain Relief, Stress Relief and Anti Ageing Restoration","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"hz Clinic","has_results":false},{"nct_id":"NCT06955351","title":"REsuscitation Survey of Police Officers in New Taipei City for Duty","phase":"","overall_status":"COMPLETED","enrollment_count":4867,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT06598553","title":"What Works to Prevent Violence Against Women and Girls in Madagascar","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4500,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT05439044","title":"A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Prophylaxis and Curative of Covid-19 (COVIMAB)","phase":"","overall_status":"COMPLETED","enrollment_count":4235,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07317869","title":"Impact Evaluation of the Therapeutic Initiative's Prescribing Portrait and Therapeutics Letter on Opioid Use by Dentists","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3498,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT05455073","title":"Evaluation of School-based Nutrition Intervention for Adolescents in Bangladesh","phase":"NA","overall_status":"COMPLETED","enrollment_count":3018,"lead_sponsor_name":"Nutrition International","has_results":false},{"nct_id":"NCT04489693","title":"Comprehensive Care Community and Culture Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT07373444","title":"Westlake Aging Cohort (WeAC)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2800,"lead_sponsor_name":"Westlake University","has_results":false},{"nct_id":"NCT07011368","title":"Empowering Healthy Lifestyle Personalised Intervention to Prevent and Control Obesity: The HealthyW8 Project","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2720,"lead_sponsor_name":"Fundació d'investigació Sanitària de les Illes Balears","has_results":false},{"nct_id":"NCT04037787","title":"ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Colorectal Cancer Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":2397,"lead_sponsor_name":"Ospedale Santa Croce-Carle Cuneo","has_results":false},{"nct_id":"NCT01745263","title":"DO-HEALTH / Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2157,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT04229966","title":"Prospective, Observational Real-world Treatments of AEDH in Large-scale Surgical Cases","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04042064","title":"To Investigate the Influence of Surgery and Anesthesia on Elderly Population by Using the Comprehensive Geriatric Assessment","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03453502","title":"Improving Mother Milk Feeding Benefits in Neonatal Intensive Care Units","phase":"NA","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Nanjing Medical University","has_results":false},{"nct_id":"NCT03317639","title":"Improving In-hospital Stroke Service Utilisation in China","phase":"NA","overall_status":"COMPLETED","enrollment_count":1634,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03474601","title":"Seoul National University Pituitary Disease Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1600,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04384211","title":"QOCA®-Image Medical Platform - Smart VCF Risk Management System","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Taipei Medical University WanFang Hospital","has_results":false},{"nct_id":"NCT04383379","title":"To Improve the Rate of Mother's Own Milk Feeding of Premature Infants in NICU","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Nanjing Medical University","has_results":false},{"nct_id":"NCT03882684","title":"Role of Genomic Imprinting in Cancer Diagnosis","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Chinese Alliance Against Lung Cancer","has_results":false},{"nct_id":"NCT03772847","title":"Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1189,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06153576","title":"The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures","phase":"","overall_status":"COMPLETED","enrollment_count":1120,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT03565575","title":"Manicaland PrEP Uptake Through Interactive Counselling Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":1055,"lead_sponsor_name":"Simon Gregson","has_results":false},{"nct_id":"NCT05420064","title":"An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06344598","title":"Identification and Assessment of Risk Factors for the Development of Osteoporosis in Adults and Children Living in the Abay Region of the Republic of Kazakhstan Using the Method of Dual-energy X-ray Absorptiometry and Clinical and Epidemiological Research","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Semey State Medical University","has_results":false},{"nct_id":"NCT07033871","title":"Comprehensive Geriatric Assessment in Chronic Disease Management for Older Adults in China: A Registry Study （CGACDM - Older Adults in China）","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Henan Provincial People's Hospital","has_results":false},{"nct_id":"NCT07507565","title":"Comparison of Analgetic Therapies in Traumatic Vertebral Compression Fractures: Vertebroplasty vs Thermal Facet Ablation.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Szeged University","has_results":false},{"nct_id":"NCT06976541","title":"Utilization Study and Evaluation of Educational Intervention on HbA1c Testing","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":968,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT05343559","title":"First Impressions and Attractiveness Levels of Smiling Individuals With and Without a Mask","phase":"","overall_status":"COMPLETED","enrollment_count":808,"lead_sponsor_name":"DeNova Research","has_results":false},{"nct_id":"NCT07397013","title":"Adjustment Technique for Occlusal Stabilizing Splint","phase":"NA","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT04043793","title":"ICU-acquired Colonization and Infection Related to MDR in Immunocompromised Patients","phase":"","overall_status":"COMPLETED","enrollment_count":759,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT03724695","title":"Advanced Heart Care at Home","phase":"NA","overall_status":"COMPLETED","enrollment_count":709,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06925243","title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":682,"lead_sponsor_name":"Zuoyi Jiao","has_results":false},{"nct_id":"NCT06949033","title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":668,"lead_sponsor_name":"Zuoyi Jiao","has_results":false},{"nct_id":"NCT03189550","title":"Enhanced Recovery After Surgery in Colorectal Surgery: A Large-Scale Quality Improvement Project","phase":"","overall_status":"COMPLETED","enrollment_count":664,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT06599658","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":660,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT05407129","title":"Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences","phase":"NA","overall_status":"RECRUITING","enrollment_count":656,"lead_sponsor_name":"Boston Children's Hospital","has_results":false},{"nct_id":"NCT04805125","title":"Immunocompromised Swiss Cohorts Based Trial Platform","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":610,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT06657625","title":"Impact of the Introduction of a Performance Improvement Program on the Initial Management of Sepsis and Septic Shock in Adults in the Emergency Department: a Before-and-after Study (IPA-SOS)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":600,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT06379243","title":"Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures","phase":"NA","overall_status":"RECRUITING","enrollment_count":560,"lead_sponsor_name":"The Seventh Affiliated Hospital of Sun Yat-sen University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}